Biotherapeutics News and Research

RSS

New microfluidic Organ Chip platform replicates the human vaginal tissue microenvironment

The human microbiome has been a hot topic over the last decade, with research pointing to disrupted bacterial communities as culprits for a host of maladies including irritable bowel syndrome, eczema, and autoimmune diseases.

28 Nov 2022

Discovery could lead to new mantle cell lymphoma drugs

A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers.

22 Nov 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

Mechanistic insights into engineered ACE2 receptor traps

Researchers determined the cryo-electron microscopic (cryo-EM) structures of engineered angiotensin-converting enzyme 2 (ACE2) receptor traps.

12 Aug 2022

Using CRISPR to Lift the Lid on Probiotics

In this interview, we speak to Echo Pan, a Ph.D. student from North Carolina State University about her latest research that used CRISPR to uncover more on probiotics.

26 Jul 2022

New technology may enable rapid diagnosis of Ebola virus

A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a study by researchers at Washington University School of Medicine in St. Louis and colleagues at other institutions.

8 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

NIH awards $577 million to establish AViDD Centers for Pathogens of Pandemic Concern

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

18 May 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022

Flow Eighteen38 receives €5 million EUR (c.$5.58 million USD) to expand production and biophysical capabilities

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, today announced a €5 million EUR (c.$5.58 million USD) investment into its protein production and biophysical characterization capabilities and services from its parent company, FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies.

From FairJourney Biologics S.A. 8 Mar 2022

Harvard’s new kidney engineering technology licensed to San Diego-based Trestle Biotherapeutics

A newly launched startup is building upon innovations developed over several years at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard John A. Paulson School of Engineering & Applied Sciences (SEAS), and Brigham and Women’s Hospital (Brigham) to engineer functional kidney tissue for renal repair and replacement therapy.

25 Feb 2022

Antibiotic treatment after birth affects a newborn's gut microbiome

Treating babies with antibiotics in the first week of life is linked with a decrease in healthy bacteria necessary amongst others to digest milk and an increase in antimicrobial resistance, research suggests.

18 Feb 2022

Accurate prediction of COVID-19 outbreaks using location data from mobile devices

Researchers at the Yale School of Public Health were able to accurately predict outbreaks of COVID-19 in Connecticut municipalities using anonymous location information from mobile devices, according to a new study published in Science Advances.

31 Jan 2022

Oral supplement appears to promote muscle endurance and mitochondrial health in humans

An oral supplement intended to stimulate a natural body process appears to promote muscle endurance and mitochondrial health in humans.

20 Jan 2022

Success of covid antiviral pills hinges on access to speedy and accurate tests

Within a few weeks, perhaps before many Americans finish decorating for the holidays, the U.S. could have access to a new antiviral pill from Merck expected to alter the deadly trajectory of the covid-19 pandemic — with a second option from Pfizer to follow shortly after.

22 Nov 2021

How to achieve fast, accurate and reliable quantitation of AAV serotypes

In this interview, News-Medical talks to Indrani Chakraborty from GatorBio about how they have achieved accurate and reliable quantitation of AAV serotypes.

From Gator Bio, Inc. 19 Nov 2021

MHRA approves first oral antiviral for the treatment of COVID-19

The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency announced today.

4 Nov 2021

RedShift BioAnalytics Celebrates Opening of StructIR Scientific Services Lab with the Launch of the StructIR Lab Grant Program

RedShift BioAnalytics announced the opening of their scientific services lab, StructIR Lab.

From RedShiftBio 7 Oct 2021